文章：

费城染色体阴性B细胞前体急性淋巴细胞白血病的一线治疗及贝林妥欧单抗的新兴作用

Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab

原文发布日期：2024-11-19

DOI: 10.1038/s41408-024-01179-4

类型: Review Article

开放获取: 是

英文摘要：

This narrative review seeks to summarize chemotherapeutic regimens commonly used for patients with newly diagnosed Philadelphia (Ph) chromosome–negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in the frontline setting and to describe the latest clinical research using the bispecific T-cell–engaging immunotherapy blinatumomab in the first-line treatment setting. Current standard-of-care chemotherapeutic backbones for newly diagnosed Ph-negative BCP-ALL are based on the same overarching treatment principle: to reduce disease burden to undetectable levels and maintain lasting remission. The adult treatment landscape has progressively evolved following the adoption of pediatric-inspired regimens. However, these intense regimens are not tolerated by all, and high-risk patients still have inferior outcomes. Therefore, designing more effective and less toxic strategies remains key to further improving efficacy and safety outcomes. Overall, the treatment landscape is evolving in the frontline, and integration of blinatumomab into different standard frontline regimens may improve overall outcomes with a favorable safety profile.
 

摘要翻译： 

本叙述性综述旨在总结费城染色体阴性B细胞前体急性淋巴细胞白血病初诊患者一线治疗中常用的化疗方案，并阐述双特异性T细胞衔接免疫疗法贝林妥欧单抗在一线治疗中的最新临床研究。当前费城染色体阴性B细胞前体急性淋巴细胞白血病初诊患者的标准化疗方案基于相同的核心治疗原则：将疾病负荷降至不可检测水平并维持长期缓解。随着儿童方案改良方案的推广应用，成人治疗模式已逐步发展。然而并非所有患者都能耐受这些强化方案，高危患者预后仍然较差。因此，设计更有效且毒性更低的治疗方案仍是进一步提高疗效与安全性的关键。总体而言，一线治疗模式正在不断发展，将贝林妥欧单抗整合至不同标准一线方案可能会改善整体疗效，并具有良好的安全性特征。

原文链接：

Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab